A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
{{output}}
Introduction: Real-world management of moderate-to-severe atopic dermatitis (AD) may involve treatment interruptions. This indirect comparison evaluated the efficacy of lebrikizumab, dupilumab, and tralokinumab monotherapy in ach... ...
